Orion Marine Group, Inc. (NYSE:ORN), a leading heavy civil marine contractor serving the infrastructure sector, recently announced a contract award of approximately $12 million.

Acadia Pharmaceuticals is a small development-stage drug firm, focused on a single late stage candidate for treatment of psychosis stemming from Parkinson's disease. The loss of their development partner, setbacks in Phase III trials, and a poor history of success makes this one risky investment.